MEGAN ULE: Open Payments
NPI 1245926419 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,617 in 86 payments from 15 companies in 2025. Trend: 2023 $395 · 2024 $1,570 · 2025 $1,617
Food & beverage: $1,540Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 48 | $634 |
| Janssen Biotech, Inc. | 9 | $230 |
| Ardelyx, Inc. | 10 | $212 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| Madrigal Pharmaceuticals | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| QOL Medical, LLC | 2 | $37 |
| VIVUS LLC | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Ferring Pharmaceuticals Inc. | 1 | $32 |
Products named: TREMFYA, CREON, IBSRELA, LINZESS, REZDIFFRA, SKYRIZI, RINVOQ, ENTYVIO.
Industry payments across TX — which companies pay providers there.
